Latest Breaking News On - Swiss approval - Page 4 : comparemela.com

Share: Esperion Therapeutics (NASDAQ: ESPR) shares are trading higher on Wednesday after the company announced Swiss Approval for the first-in-class cholesterol-lowering treatment NILEMDO and its Combination with NUSTENDI. Esprit Holdings is an international fashion brand whose operations include Retail, Wholesale and Licensing. It produces garments that are sold at its directly managed retail outlets. Esperion Therapeutics shares were trading down 1.77% at $27.67. The stock has a 52-week high of $76.98 and a 52-week low of $23.90. Anika Therapeutics (NASDAQ: ANIK) shares are trading higher after Barrington Research upgraded the stock from Market Perform to Outperform and announced a price target of $43 per share.

Anika therapeuticsEsprit holdingsBarrington researchHeat biologics incEsperion therapeuticsSwiss approvalMarket performBiologics incஅணைக்க சிகிச்சைஎஸ்பிரிட் ஹோல்டிங்ஸ்பாரிங்டன் ஆராய்ச்சிவெப்பம் உயிரியல் இன்க்சுவிஸ் ஒப்புதல்சந்தை செய்யஉயிரியல் இன்க்